CN1045160C - 毛发生长修饰剂 - Google Patents
毛发生长修饰剂 Download PDFInfo
- Publication number
- CN1045160C CN1045160C CN85108498A CN85108498A CN1045160C CN 1045160 C CN1045160 C CN 1045160C CN 85108498 A CN85108498 A CN 85108498A CN 85108498 A CN85108498 A CN 85108498A CN 1045160 C CN1045160 C CN 1045160C
- Authority
- CN
- China
- Prior art keywords
- alpha
- methyl
- substance
- skin
- hydroxyprogesterone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003779 hair growth Effects 0.000 title abstract description 13
- 239000003607 modifier Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 102000052812 Ornithine decarboxylases Human genes 0.000 claims abstract description 29
- 108700005126 Ornithine decarboxylases Proteins 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 29
- 210000004209 hair Anatomy 0.000 claims abstract description 17
- 230000002280 anti-androgenic effect Effects 0.000 claims abstract description 10
- 230000012010 growth Effects 0.000 claims abstract description 10
- 239000002537 cosmetic Substances 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract 19
- 230000002401 inhibitory effect Effects 0.000 claims abstract 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 24
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 12
- 239000000186 progesterone Substances 0.000 claims description 12
- 229960003387 progesterone Drugs 0.000 claims description 12
- 239000003098 androgen Substances 0.000 claims description 11
- 239000000051 antiandrogen Substances 0.000 claims description 9
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims description 8
- -1 2-methyl-6-heptynylhydrazine Chemical compound 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 claims description 4
- 229960001616 chlormadinone acetate Drugs 0.000 claims description 4
- RWBRUCCWZPSBFC-RXRZZTMXSA-N (20S)-20-hydroxypregn-4-en-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](O)C)[C@@]1(C)CC2 RWBRUCCWZPSBFC-RXRZZTMXSA-N 0.000 claims description 3
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 claims description 3
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 claims description 3
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 claims description 3
- 150000004702 methyl esters Chemical class 0.000 claims description 3
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical class C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 3
- BFZHCUBIASXHPK-QJSKAATBSA-N 11alpha-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)C[C@H]2O BFZHCUBIASXHPK-QJSKAATBSA-N 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 229960002256 spironolactone Drugs 0.000 claims description 2
- ZUIGZKIOHUNINA-LWPUPYOYSA-N (1s,3as,3br,5s,5as,9ar,9bs,11as)-5-bromo-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,8,9,9b,10,11-dodecahydroindeno[5,4-f]chromen-7-one Chemical compound O([C@@H]1[C@@H](Br)C2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ZUIGZKIOHUNINA-LWPUPYOYSA-N 0.000 claims 2
- DFRQHISHXQPKMU-GUCLMQHLSA-N (8r,9s,10r,13s,14s,17r)-17-hydroxy-10,13-dimethyl-17-prop-2-enyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)CC=C)[C@@H]4[C@@H]3CCC2=C1 DFRQHISHXQPKMU-GUCLMQHLSA-N 0.000 claims 2
- YQACAXHKQZCEOI-SCZYCMLPSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-17-carboxylic acid Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)C(O)=O)[C@@H]4[C@@H]3CCC2=C1 YQACAXHKQZCEOI-SCZYCMLPSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- LZSOOHLAZHOTHJ-GUCLMQHLSA-N topterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](CCC)(O)[C@@]1(C)CC2 LZSOOHLAZHOTHJ-GUCLMQHLSA-N 0.000 claims 2
- JWWZUFCRQMJENK-ZETCQYMHSA-N (2r)-2,5-diamino-2-ethynylpentanoic acid Chemical compound NCCC[C@@](N)(C#C)C(O)=O JWWZUFCRQMJENK-ZETCQYMHSA-N 0.000 claims 1
- MLPGZRVFTNWGPH-UXJQAVHOSA-N (5r,8s,9s,10r,13s,14s,17r)-4-diazonio-17-[(2r)-1-hydroxypropan-2-yl]-10,13-dimethyl-2,5,6,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-olate Chemical compound N#[N+]C([C@@H]1CC2)=C([O-])CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](CO)C)[C@@]2(C)CC1 MLPGZRVFTNWGPH-UXJQAVHOSA-N 0.000 claims 1
- SLDJDCVFAACINK-UHFFFAOYSA-N NN.CC(C)CCCC#C Chemical compound NN.CC(C)CCCC#C SLDJDCVFAACINK-UHFFFAOYSA-N 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 102000001307 androgen receptors Human genes 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 108091008039 hormone receptors Proteins 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- RJKFOVLPORLFTN-UHFFFAOYSA-N progesterone acetate Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 RJKFOVLPORLFTN-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 239000003112 inhibitor Substances 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 11
- 230000001154 acute effect Effects 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 229920000768 polyamine Polymers 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229960003604 testosterone Drugs 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical class NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000699800 Cricetinae Species 0.000 description 6
- 206010020112 Hirsutism Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000005700 Putrescine Substances 0.000 description 5
- 239000007767 bonding agent Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000000172 cytosol Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 239000008279 sol Substances 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- OIRDTQYFTABQOQ-UHFFFAOYSA-N ara-adenosine Natural products Nc1ncnc2n(cnc12)C1OC(CO)C(O)C1O OIRDTQYFTABQOQ-UHFFFAOYSA-N 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229940063673 spermidine Drugs 0.000 description 3
- QWWVBNODQCWBAZ-WHFBIAKZSA-N (2r)-2-amino-3-[(2r)-2-carboxy-2-(methylamino)ethyl]sulfanylpropanoic acid Chemical compound CN[C@H](C(O)=O)CSC[C@H](N)C(O)=O QWWVBNODQCWBAZ-WHFBIAKZSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000001548 androgenic effect Effects 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 2
- 229960003843 cyproterone Drugs 0.000 description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229960003151 mercaptamine Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229950000064 topterone Drugs 0.000 description 2
- SXQWVGXLKTZECH-UHFFFAOYSA-N 2,2-diaminopentanoic acid Chemical compound CCCC(N)(N)C(O)=O SXQWVGXLKTZECH-UHFFFAOYSA-N 0.000 description 1
- PWVUXRBUUYZMKM-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCO PWVUXRBUUYZMKM-UHFFFAOYSA-N 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- CODOVMCZKJILBE-UHFFFAOYSA-N 6-methylhept-1-yne Chemical compound CC(C)CCCC#C CODOVMCZKJILBE-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- GZTXCXATONSQBP-UHFFFAOYSA-N C=CCCCCC.NNC(NN)=O Chemical compound C=CCCCCC.NNC(NN)=O GZTXCXATONSQBP-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229940048299 acetylated lanolin alcohols Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229940031768 diglycol stearate Drugs 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- YVXHZKKCZYLQOP-UHFFFAOYSA-N hept-1-yne Chemical compound CCCCCC#C YVXHZKKCZYLQOP-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
- A61Q7/02—Preparations for inhibiting or slowing hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Massaging Devices (AREA)
- Magnetic Treatment Devices (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
一种用于降低人类毛发生长速率和改变人类毛发生长特征的化妆方法,其特征在于往皮肤上施用含有具有抑制鸟氨酸脱羧酶的作用物质的组合物。在本发明的最佳实例中,使用了含有类似物质同抗雄性激素物质的组合物。
Description
本发明涉及一种通过局部使用含有能够抑制具有增加毛囊基质细胞的增生活性的鸟氨酸脱羧酶活性的物质以改变人类毛发生长的特性并减缓其速度的新颖的方法。
鸟氨酸对腐胺的脱羧作用,即一个由鸟氨酸脱羧酶(ODC)催化的反应,是已知为精氨和亚精胺类的多胺的生物合成的第一步。亚精胺是将一活性氨丙基部分从S-腺苷S-甲基同型半胱胺上转移到腐胺上形成的,精胺是将又一个氨丙基移到亚精胺上合成的。S-腺苷S-甲基同型半胱胺是由S腺苷硫氨酸脱羧而形成的,这步反应是由S-腺苷硫氨酸(SAM)脱羧酶(SAM-DC)催化的。
多胺,发现于动物组织和微生物中,已知其在细胞生长和增殖上起重要作用。细胞生长和增殖的超始是和ODC活性的显著增强以及腐胺和多胺的水平的增加相联系的。虽然多胺在细胞生长和增殖中的准确的作用机制还不明了,但显然多胺可促进DNA,RNA或蛋白质等大分子的合成过程。多胺的水平在胚胎组织中甚高是已知的,例如在睾丸、腹面组织(Ventral prostrato)胸腺、肿瘤组织,牛皮癣皮肤损伤和其它快速生长和增殖的细胞中。因为腐胺是亚精胺和精胺的前体,所以阻断鸟酸向腐胺的转化,例如通过ODC的抑制,将能阻止多胺的新的生物合成并因此产生有益的生理效应。
为说明毛发生长机制所进行的药物研究多数集中在内分泌系统的作用上。作为这种调查的结果,一般均认为纤细的、浅色毫毛,即童年时覆盖身体大部分的毛发,在生长激素和雄激素的影响下渐趋成熟,最终成为较粗、较黑的成人身体许多部位特征的最终毛发。对揭示控制雄激素依赖条件的方法的需要已导致了大量的有关雄激素在皮肤中代谢的研究。这些研究使人联想到可以用两种方法减少能够进入毛发生长周期的雄激素的数量。
首先,血浆中睾酮转化成二氢睾酮可通过类固醇5-α-还原酶的抑制而被阻止。其次,某些化合物可与睾酮或二氢睾酮竞争细胞质受体位点。皮肤中的两类抗雄性激素化合物的作用也可影响女性中的男性类型毛发生长的过程,从而导致了它们在女性多毛症的治疗中的应用。其中的一些这类应用在下述专利中述及:
美国专利第4,139,638号和4,151,540号描述了某些4′取代和3′,4′一双取代酰替苯胺用于治疗雄性激素依赖的疾病,例如女性多毛症和粉刺。
美国专利第4,191,775号描述了某些3,4-双取代支链氟化脂酰苯胺可用于局部治疗雄性激素依赖的疾病,例如粉刺、女性多毛症和皮脂溢。
美国专利第4,344,942号描述了局部应用某些雄性激素17-α-取代类固醇,例如17-β-羟基-1-α-甲基-17-α(1-甲基-2-丙烯基)-5-α-雄甾烷-3-酮,以治疗粉刺、皮脂溢、脱发和女性多毛症。
西德OLS第2,840,144号描述了使用5-α-还原酶抑制剂孕甾酮与环孕酮乙酸酯或氯地孕酮乙酸酯的混合剂局部治疗雄激素诱导的荷尔蒙紊乱,例如脱发、女性多毛症和粉刺。
专利文献还揭示了大量的非类固醇性减缓人类毛发生长的方法,而且与常见的用剃、刮和拔毛的去毛方法相反。在美国专利第3,426,137号中描述了一种这类方法,该方法是关于一种通过局部使用一种含有一取代苯酮的,例如2-氨基5-氯苯酮的合成物于脱毛区皮肤上以抑制毛发生长的过程。专利中的实例说明了兔背和男性供试者手臂毛发生长的减缓。
另一种延长脱毛时限的方法在美国专利第4,370,315号中进行了描述。该过程包括局部应用含有脂肪氧合酶以及亚油酸及其衍生物的合成物。专利描述了这种合成物应用于女性供试者身体各部位,其中大多数毛发的再生只在六周或更长的时间后才明显可见。
对鸟氨酸脱羧酶直到六十年代后期才基本上有所了解。在直到认识到其活性是哺乳动物所产生的多胺的生物合成的限速步骤之前,对该酶的认识一直相当模糊。这一发现的应用导致了在各种病例的治疗中使用ODC抑制剂。描述这类应用的先有技术资料主要包括:
美国专利第4,413,141号是有关2-二氟甲基(2,5-二氨基戊)酸或其盐作为Contragestational用于良性前列腺肥大,减缓瘤细胞的增殖以及作为抗原生动物剂。
美国专利第4,421,768号是关于氟化二氨基庚烯及其庚炔衍生物用于控制肿瘤组织快速增殖的生长率以及用于控制致病寄生原生动物的生长。
美国专利第4,207,315号描述了一种应用脂肪族碳氢化合物肼或与一制药载体相结合的鸟氨酸衍生物治疗非恶性增生皮肤病的方法。
美国专利第4,201,788号描述了一种使用与一制药载体相结合的甲基乙二醛双-(脒基-腙)类化合物治疗恶性皮肤增生症的方法。
我已经发现了各种各样的鸟氨酸脱羧酶活性抑制剂(ODCinhjbitors)可用于改变包括未受损的、性成熟男性的胡须的雄激素刺激毛发的生长的速率和特征。ODC抑制剂局部外用—皮肤学可接受的载体以寻求通过内吸作用其它全身作用的最小改变所伴随的区域效果。在本发明的一个具体实例中,使用了含有ODC抑制剂以及b-α-还原酶抑制剂和(或)胞质受体结合剂的组合物。
我发现人类毛发生长的正常速率和特征,包括男性须发的生长,可通过局部施用抑制鸟氨酸脱羧酶活性的化合物再被改变。通过对ODC抑制剂及其使用方式的适当选择,对其它全身反应的不必要的妨碍可以被减到最少甚或避免。
在局部使用ODC抑制剂以改变毛发生长的速率和特征时,可单独使用各种ODC抑制剂或同5-α-还原酶抑制剂和(或)胞质受体结合剂结合使用。可应用的ODC抑制剂中有已在美国专利第4,201,788号;4,413,141号;和4,421,768号中描述过的那些。优选的化合物包括2-(二氟甲基)-2,5-二氨基戊酸;α-乙炔基鸟氨酸;6-庚炔-2,5-肼;以及2-甲基-6-庚炔一肼。
在选择用于我们的发明实验中的ODC抑制剂时,重要的一条是避免那些已知有副作用的制剂,例如5-已炔-1,4-肼,已知它可引起脑中4-氟基丁酸水平的上升,该结果是由线粒体单胺氧化酶所催化的一步转化的作用。为了把通过系统作用而引起的其他全身功能改变的危险降低到最低限度,我优先选用的ODC抑制剂组合物用量在每平方厘米皮肤上在从1到2000毫克活性物质的范围内。我选择的组合物的用量为每平方厘米50到500毫克。
本发明的最佳实例中,所用的组合物除含有ODC抑制剂外还有5-α-还原酶抑制剂和(或)胞质结合剂,按配方配制的混合物中的后几种物质的使用浓度和水平应为1到1000毫克活性物质用于每平方厘米皮肤上。我选择了那些用量为每平方厘米10到100毫克的5-α-还原酶抑制剂和(或)胞质结合剂的组合物。
在5-α-还原酶抑制剂中可以使用的有孕甾酮;[5α,20-R]-4-重氮基-21-羟基-20-甲基孕甾烷-3-酮;[4R]-5-10-开环-19-去甲孕甾烷-4,5-二烯-3,10,20-三酮;4-雄甾烯-3-酮-17-羧酸及其甲酯;17-β-N,N-二乙氨基甲酰-9-甲基-14-氮杂-5-α-雄甾烷-3-酮;11-α-羟基孕甾酮;17-α-羟基孕甾酮和20-α-羟基孕甾酮。为使通过内吸作用而产生的雄激素引起的其它全身功能的变化最小,我们选用了孕甾酮或4-雄甾烯-3-酮-17-羧酸。
在胞质受体结合剂中可以使用的有环孕酮乙酸酯,氯地孕酮乙酸酯,17-α-丙基睾酮,17-α-烯丙基睾酮,α-α-α三氟代-2-甲基,4′-硝基-间-丙酰替甲苯胺;6α-溴代-17-β-羟基-17α-甲基-4-氧杂-5α-雄甾烷-3-酮;17β-乙酸基-4α,5-环-A-高-B-去甲-5α-雄甾-1-烯-3-酮;以及螺甾内酯。为使通过内吸作用而产生的雄激素引起的其他全身功能的变化降到最低限度,我们选用了17-α-丙基睾酮或17-α烯丙基睾酮。
为表明在局部施用2-(二氟代-甲基)-2,5-二氨基戊酸以直接抑制ODC后在雄性仓鼠中雄激素引起的毛发生长的抑制我们做了一个试验。将500毫克化合物溶于10毫升70%乙醇中,并局部连续施用21天。毛发变化通过对最后十天内毛发再生物的比较而确定。发现侧面器官ODC活性降到仓鼠阉割21天后的水平上了。进而,在用ODC抑制剂处理过的仓鼠中的毛片抑制的量接近于21日龄阉割仓鼠(78%)。
为试验由2-(二氟代-甲基)-2,5-二氨基戊酸和抗雄激素物质组成的混合物的局部影响进行了附加的试验。总结于下面的表I和表II的是两个试验的结果,比较了几种组合物对成熟雄性未受损仓鼠在减少一侧毛片上的效果。每种情况下在21天期间对仓鼠处理15天(从周一到周五)。一侧毛发在处理的第1天被脱去,并在第6天再次脱去。身体侧面的毛片代表着21天期间中的后14天中再生毛发。下面表示的抑制百分比的结果建立在从试验动物的处理侧身体上剪下的毛发的毛片等级以及那些从不发生化学反应的药用混合物处理过的对照动物上所得到的数据的比较的基础上。
表I
每平方厘米 抑制率化合物
施用毫克数 %孕酮 1000 502-(二氟代甲基)-2,5-二氨基戊酸 500 46孕酮和2-(二氟代甲基) 1000-2,5-二氨基戊酸混合物 500 66
表II
每平方厘米 抑制率化合物
施用毫克数 %氯地孕酮乙酸酯 500 412-(二氟代甲基)-2,5-二氨基戊酸 500 41氯地孕酮和 5002-(二氟代甲基)-2,5-二氨基戊酸混合物 500 66上述结果表明了由一个ODC抑制剂和一个抗雄激素物质组成的混合物局部作用效果的增进及其抑制毛片的综合作用的规模比单一化合物作用所达到的更大。
一条列类似的试验导致了下表的各种混合物作用比较结果。(表III、表III续见文后)
在配制用于本发明试验中局部使用的组合物过程中,任何皮肤学上可以接受的基质或载体都可以使用。但应当注意使用那些能使活性成份均匀局部吸收而不产生明显的全身吸收作用的基质或载体。配制化妆用雪花膏的技术对用于本发明实践中的组合物的配制极其有用。例如,许多羊毛脂的衍生物已知具有极好的乳化特性并可用于使具有严格的稳定性要求的乳剂易于配制。羊毛脂还被认为有助于皮肤对活性物质的吸收。活性物质可与各种各样的化妆品基质类物质,诸如单一溶液,乳剂,悬浮剂,凝胶等混合,但油包水型乳剂则更优越,因其具有连续油相并使其与皮肤上的脂肪直接接触,因而提供了一条缓慢连续吸收活性成份的途径。
本发明组合物的配制中,可能包括少到0.01%或多至20%的以重量计的ODC抑制剂。我们优选以重量计从0.1%到2.5%。在配制那些还含有5-α-还原酶抑制剂和(或)胞质受体结合剂组合物时,以这些物质的重量计可使用从0.01%到10%浓度。但我们优选以重量计从0.1%到2.5%的范围。
在使用此处所描述的含有ODC抑制剂的组合物以降低并改变包括须发在内的毛发生长的速率和特征时,最好能每天将足量的组合物擦入多毛皮肤区,以达到前面已论述过的使用水平的用量为好。所能达到的最大变化百分比将随个体的不同而不同。
下面的实例是用于本发明试验中的组合物的说明,但并不限制本发明。
实例1-皮肤洗液
成份 重量%
2-(二氟代甲基)-2,5-
二氨基戊酸 2.0
孕酮 2.2
十六烷醇 4.0
矿物油 4.0
异丙基肉豆蔻酸酯 1.0
二甲聚硅氧烷 1.0
羊毛脂醇 0.5
甘油单硬脂酸酯 1.0
乳酸钠(60%水溶液) 1.4
二甲基氯化二铵(75%活性)-
Arquad 2HT75 2.0
丙烯甘醇 3.0
羟苯甲酸甲酯 0.2
对羟苯甲酸丙酯 0.1
二氧化钛 0.1
香精 0.1
水 75.4
流程:去离子水和丙烯甘醇加热至70℃。高速搅拌下加入羟苯甲酸甲酯。在另一容器中将润肤油、乳化剂、预热的二甲基氯化二铵、活性成份和对羟苯甲酸丙酯混合。加热并在缓慢搅拌下保持70℃ 30分钟。将水相加入到油相中并缓慢搅拌。加入二氧化钛并混合60分钟。慢慢冷至55℃,加入(60%)乳酸钠并在搅拌下继续慢慢冷却至室温。
实例2-乳剂
浓缩剂 W/W%
A2-(二氟代甲基)-2,
5-二氨基戊酸 2.2
17-α-烯丙基睾酮 1.5
硬脂酸XXX 7.6
AmercolI-lol 5.0
Modulon 2.0
十六烷醇 3.0
propyl parasopt 0.1
B甘油 4.0
羟苯甲酸甲酯 0.15
水 74.45
流程:(A)组份混匀并加热到70℃。另外将(B)组份混合并加热到72℃。快速搅拌下将(B)加入(A)中,随后降至室温。
实例3-汽溶胶喷雾剂
浓缩剂 W/W%
A铝硅酸镁盐(Veegumk) 1.5
丙烯甘醇 3.0
水 86.0
B2-甲基-6-庚炔肼 2.2
二甘醇单硬脂酸酯S.e. 3.0
硅酮556液 1.0
十六烷醇 0.5
乙酰化羊毛脂醇 2.0
防腐剂 0.2
流程:快速搅拌下将铝硅酸镁盐(Veegum)慢慢加入到水中直到混合匀为止。(A)剩余部分加入并加热至80℃。(B)组份混合并加热到75℃。将(A)加入(B)混合并冷却至室温。将90份浓缩剂与10份烃推进剂A-46混匀,象汽溶胶一样包装。
实施4-汽溶胶泡沫
浓缩剂 W/W%
A孕酮 2.0
6-庚炔-2,5肼 0.2
十六烷醇 5.2
聚乙二醇[401硬脂酸酯
(MYRJ52)] 3.0
B丙烯甘醇 4.0
水 85.4
防腐剂 0.2
流程:(A)组份混匀,加热至70℃。另外将(B)组份混匀,加热到72℃。(B)加入于(A)中混合,冷却至室温。以7份氢推进剂A-37与93份浓缩剂的比例制成汽溶胶,包装好。
实例5-乙醇溶液
浓缩剂 W/W%
2-(二氟代甲基)-2,
5-二氨基戊酸 2.2
孕酮 1.0
17-α-烯丙基睾酮 1.0
丙烯甘醇 4.0
二甲基硅氧烷 1.0
SDA-40乙醇 90.8
流程:各组份混合均匀并包装。
表III
试验组 每平方厘米 一侧毛片 抑制率
施用毫克数 未处理 处理 %
对照 - 2.62 2.68 -
阉割 - 0.95 0.97 -2-(二氟代甲基)- 5 3.26 3.20 22,5-二氨基戊酸
同上 50 3.05 2.85 7
同上 250 3.00 2.29 24
同上 500 2.71 1.81 332-(二氟代甲基)- 5002,5-二氨基戊酸和 2.86 1.45 4917-α-烯丙基 20睾酮混合物2-(二氟代甲基) 500
表III(续)
试验组 每平方厘米 一侧毛片 抑制率
施用毫克数 未处理 处理 %-2,5-二氨基戊酸 2.31 1.33 42和孕酮混合物 4002-(二氟代甲基) 500-2,5-二氨基戊酸 2.89 1.14 61与孕酮以及17-α- 400烯丙基睾酮混合物 20
Claims (9)
1.一种用于降低人类毛发生长速率和改变人类毛发生长特征的化妆方法,其特征在于,往皮肤上施用含有具有抑制鸟氨酸脱羧酶的作用物质的组合物。
2.根据权利要求1所述的方法,其中所述的物质是从包括2-(二氟代甲基)-2,5-二氨基戊酸,α-乙炔基鸟氨酸,6-度炔-2,5-肼,以及2-甲基-6-庚炔肼在内的一类物质中选出来的。
3.根据权利要求2所述的方法,导致了每平方厘米的皮肤使用从1毫克到2000毫克的上述物质。
4.根据权利要求2所述的方法,结果在于每平方厘米皮肤上所述物质的用量从50毫克到500毫克。
5.根据权利要求1所述的方法,其中所述的组合物还有一种选自包括5-α-还原酶抑制剂和胞质雄性激素受体接合剂类的抗雄性激素物质。
6.根据权利要求5所述的方法,其中所述的抗雄性激素物质选自包括孕甾酮;(5α,20-R)-4-重氮基-21羟基-20-甲基孕甾烷-3-酮;(4R)-5-10-开环-19-去甲孕甾烷-4,5-二烯-3,10,20-三酮;4-雄甾烯-3-酮-17-羧酸及其甲酯;17-β-N,N-二乙氨基甲酰-9-甲基-14-氮杂-5α-雄甾烷-3-酮;11-α-羟基孕甾酮;17-α-羟基孕甾酮;以及20-α-羟基孕甾酮;环孕酮乙酸酯;氯地孕酮乙酸酯;17-α-丙基睾酮;17-α-烯丙基睾酮;α-α-α三氟代-2-甲基-4′-硝基-间-丙酰替甲苯胺;6α-溴代-17β羟基-17α-甲基-4-氧杂-5α-雄甾烷-3-酮;17β-乙酸基-4α,5-环状-A-高-β去甲-5α-雄甾-1-烯-3-酮;以及螺甾内酯在内的一类物质。
7.根据权利要求6所述的方法,结果在于每平方厘米的皮肤上所使用的所述抗雄性激素物质量为1-1000mg。
8.一种用于降低人类毛发生长速率和改变人类毛发生长特征的局部化妆品组合物,包括能抑制鸟氨酸脱羧酶动能的物质与选自含有5-α-还原酶抑制剂和胞质雄性激素受体结合剂类物质的抗雄性激素物质相结合,其中所述能抑制鸟氨酸脱羧酶功能的物质的浓度以重量计占组合物的0.01-20%,所述抗雄性激素物质的浓度以其重量计占组合物的0.01-10%。
9.根据权利要求8所述的组合物,其中所述能抑制鸟氨酸脱羧酶功能的物质选自下列物质:2-(二氟代甲基)-2,5-二氨基戊酸α;-乙炔基鸟氨酸;6-庚炔-2,5-肼;以及2-甲基-6-庚炔肼;其中所述的抗雄性激素物质选自下列物质:孕甾酮;(5α,20-R)-4-重氮基-21羟基-20-甲基孕甾烷-3-酮;(4R)-5-10-开环-19-去甲孕甾烷-4,5-二烯-3,10,20-三酮;4-雄甾烯-3-酮-17-羧酸及其甲酯;17-β-N,N-二乙氨基甲酰-9-甲基-14-氮杂-5α-雄甾烷-3-酮;11-α-羟基孕甾酮;17-α-羟基孕甾酮;20-α-羟基孕甾酮;环孕酮乙酸酯;氯地孕酮乙酸酯;17-α-丙基睾酮;17-α-烯丙基睾酮;α-α-α三氟代-2-甲基-4′-硝基-间-丙酰替甲苯胺;6α-溴代-17β-羟基-17α-甲基-4-氧杂-5α-雄甾烷-3-酮;17β-乙酸基-4α,5-环状-A-高-B-去甲-5α-雄甾-1-烯-3-酮;以及螺甾内酯。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US661,019 | 1984-10-15 | ||
| US06/661,019 US4720489A (en) | 1984-10-15 | 1984-10-15 | Hair growth modification with ornithine decarboxylase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN85108498A CN85108498A (zh) | 1986-06-10 |
| CN1045160C true CN1045160C (zh) | 1999-09-22 |
Family
ID=24651865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN85108498A Expired - Lifetime CN1045160C (zh) | 1984-10-15 | 1985-10-12 | 毛发生长修饰剂 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4720489A (zh) |
| EP (1) | EP0198893B1 (zh) |
| JP (1) | JPH0653680B2 (zh) |
| CN (1) | CN1045160C (zh) |
| AT (1) | ATE72978T1 (zh) |
| AU (1) | AU590730B2 (zh) |
| CA (1) | CA1262335A (zh) |
| DE (1) | DE3585526D1 (zh) |
| DK (1) | DK166801B1 (zh) |
| EG (1) | EG17746A (zh) |
| GR (1) | GR852488B (zh) |
| MX (1) | MX172116B (zh) |
| NO (1) | NO174832C (zh) |
| NZ (1) | NZ213805A (zh) |
| PH (1) | PH26283A (zh) |
| WO (1) | WO1986002269A1 (zh) |
| ZA (1) | ZA857846B (zh) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4695654A (en) * | 1985-08-21 | 1987-09-22 | Merrell Dow Pharmaceuticals Inc. | Gem-dihalo-1,8-diamino-4-aza-octanes |
| US5096911A (en) * | 1990-06-25 | 1992-03-17 | Ahluwalia Gurpreet S | Alteration of rate and character of hair growth |
| DE69128034T2 (de) * | 1990-08-14 | 1998-04-16 | Handelman Joseph H | Enzymatische änderung des haarwuchses |
| US5095007A (en) * | 1990-10-24 | 1992-03-10 | Ahluwalia Gurpreet S | Alteration of rate and character of hair growth |
| US5143925A (en) * | 1990-12-20 | 1992-09-01 | Douglas Shander | Alteration of rate and character of hair growth |
| JPH06504057A (ja) * | 1990-12-20 | 1994-05-12 | ハンデルマン,ジョセフ エイチ. | 毛成長の速度及び特性の変更 |
| GB9118866D0 (en) * | 1991-09-04 | 1991-10-23 | Unilever Plc | Cosmetic composition |
| US5328686A (en) * | 1991-10-30 | 1994-07-12 | Douglas Shander | Treatment of acne or of pseudofolliculitis barbae |
| ATE218273T1 (de) * | 1991-11-05 | 2002-06-15 | Gillette Co | Veränderung der geschindigkeit und der art des haarwuchses |
| US5364885A (en) * | 1992-11-13 | 1994-11-15 | Ahluwalia Gurpreet S | Reduction of hair growth |
| US6743419B1 (en) | 1992-12-22 | 2004-06-01 | The Gillette Company | Method of reducing hair growth employing sulfhydryl active compounds |
| US5411991A (en) * | 1992-12-22 | 1995-05-02 | Shander; Douglas | Method of reducing hair growth employing sulfhydryl active compounds |
| AU3931093A (en) * | 1993-03-19 | 1994-10-11 | Handelman, Joseph H. | Topical composition for inhibiting hair growth |
| US5648394A (en) * | 1993-05-27 | 1997-07-15 | Boxall; Brian Alfred | Topical composition for inhibiting hair growth |
| US6414017B2 (en) | 1993-05-28 | 2002-07-02 | The Gillette Company | Inhibition of hair growth |
| US6248751B1 (en) * | 1993-05-28 | 2001-06-19 | Gurpreet S. Ahluwalia | Inhibition of hair growth |
| US6239170B1 (en) * | 1993-05-28 | 2001-05-29 | Gurpreet S. Ahluwalia | Inhibition of hair growth |
| US5474763A (en) * | 1994-03-11 | 1995-12-12 | Shander; Douglas | Reduction of hair growth |
| US5455234A (en) * | 1994-03-16 | 1995-10-03 | Ahluwalia; Gurpreet S. | Inhibition of hair growth |
| US5468476A (en) * | 1994-03-16 | 1995-11-21 | Ahluwalia; Gurpreet S. | Reduction of hair growth |
| JPH10508828A (ja) * | 1994-09-14 | 1998-09-02 | セントラル シェフィールド ユニバーシティ ホスピタルズ エヌエイチエス トラスト | 毛髪成長の制御 |
| US5554608A (en) * | 1994-09-28 | 1996-09-10 | Ahluwalia; Gurpreet S. | Inhibition of hair growth |
| WO1996026712A2 (en) * | 1995-02-28 | 1996-09-06 | Handelman, Joseph, H. | Use of angiogenesis suppressors for inhibiting hair growth |
| US5674477A (en) * | 1995-02-28 | 1997-10-07 | Ahluwalia; Gurpreet S. | Reduction of hair growth |
| US5728736A (en) * | 1995-11-29 | 1998-03-17 | Shander; Douglas | Reduction of hair growth |
| US5652273A (en) * | 1995-11-30 | 1997-07-29 | Henry; James | Reduction of hair growth |
| US5908867A (en) * | 1996-07-18 | 1999-06-01 | Henry; James P. | Reduction of hair growth |
| US6225299B1 (en) * | 1996-09-16 | 2001-05-01 | Jenapharm Gmbh & Co. Kg | Hormonal agent for skin treatment |
| US5840752A (en) * | 1996-11-21 | 1998-11-24 | Henry; James P. | Reduction of hair growth |
| ZA9711121B (en) * | 1996-12-13 | 1998-06-23 | Handelman Joseph H | Reduction of hair growth. |
| US6037326A (en) * | 1996-12-31 | 2000-03-14 | Styczynski; Peter | Reduction of hair growth |
| AUPO690297A0 (en) | 1997-05-20 | 1997-06-12 | Kahale, Laura | Prevention/retardation of hair growth |
| US5939458A (en) * | 1997-09-22 | 1999-08-17 | Henry; James P. | Reduction of hair growth |
| US6146620A (en) * | 1997-12-09 | 2000-11-14 | Janowski; Leonard J. | Shaving compositions useful in altering the growth of male beard hair |
| JP3973748B2 (ja) | 1998-01-14 | 2007-09-12 | 花王株式会社 | 発毛抑制剤 |
| US5958946A (en) * | 1998-01-20 | 1999-09-28 | Styczynski; Peter | Modulation of hair growth |
| US6060471A (en) * | 1998-01-21 | 2000-05-09 | Styczynski; Peter | Reduction of hair growth |
| US7425579B2 (en) * | 1998-04-21 | 2008-09-16 | Universite Laval | Methods for inhibiting activity of polyamine transporters |
| IL124764A0 (en) * | 1998-06-04 | 1999-01-26 | Univ Ben Gurion | Topical composition for treatment of baldness |
| DE19834007C1 (de) * | 1998-07-29 | 2000-02-24 | Lohmann Therapie Syst Lts | Estradiolhaltiges Pflaster zur transdermalen Applikation von Hormonen und seine Verwendung |
| US6020006A (en) * | 1998-10-27 | 2000-02-01 | The Gillette Company | Reduction of hair growth |
| US6121269A (en) * | 1999-02-22 | 2000-09-19 | Henry; James P. | Reduction of hair growth |
| US6235737B1 (en) * | 2000-01-25 | 2001-05-22 | Peter Styczynski | Reduction of hair growth |
| US6299865B1 (en) | 2000-05-02 | 2001-10-09 | Peter Styczynski | Reduction of hair growth |
| US6630511B2 (en) * | 2000-08-01 | 2003-10-07 | Rolland F. Hebert | Water-soluble salts of 2-difluoromethyl-2,5-diaminopentanoic acid (DFMO) |
| US20040047833A1 (en) * | 2000-12-22 | 2004-03-11 | Akihiro Ishino | Hair growth inhibitors and compositions containing the same |
| WO2002062341A1 (en) * | 2001-02-07 | 2002-08-15 | University Of Florida | Method and composition for the control of hair growth |
| US7439271B2 (en) * | 2001-06-27 | 2008-10-21 | The Gillette Company | Reduction of hair growth |
| JP4759182B2 (ja) * | 2001-08-03 | 2011-08-31 | 花王株式会社 | 水溶性ショウキョウエキス |
| WO2003013245A1 (en) * | 2001-08-07 | 2003-02-20 | Wisconsin Alumni Research Foundation | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
| US6743822B2 (en) * | 2001-08-10 | 2004-06-01 | The Gillette Company | Reduction of hair growth |
| US7261878B2 (en) * | 2001-08-10 | 2007-08-28 | The Gillette Company | Reduction of hair growth |
| US20030036561A1 (en) * | 2001-08-10 | 2003-02-20 | Peter Styczynski | Reduction of hair growth |
| US7374770B2 (en) * | 2001-08-15 | 2008-05-20 | Skinmedica, Inc. | Topical composition for follicular delivery of an ornithine decarboxylase inhibitor |
| US6730809B2 (en) | 2001-08-29 | 2004-05-04 | Women First Healthcare, Inc. | Processes for the production of α-difluoromethyl ornithine (DFMO) |
| US7160921B2 (en) * | 2002-01-29 | 2007-01-09 | The Gillette Company | Reduction of hair growth |
| US20040198821A1 (en) * | 2002-01-29 | 2004-10-07 | Hwang Cheng Shine | Reduction of hair growth |
| JP2005517004A (ja) * | 2002-02-07 | 2005-06-09 | ウィスコンシン アルムニ リサーチ ファンデーション | 癌治療に関連した使用に対するポリアミン化合物及び組成 |
| US20030199584A1 (en) * | 2002-04-11 | 2003-10-23 | Ahluwalia Gurpreet S. | Reduction of hair growth |
| US20040077593A1 (en) * | 2002-10-21 | 2004-04-22 | Marron Susan M. | Numbing gel for hair removal |
| US20040141935A1 (en) * | 2003-01-21 | 2004-07-22 | Peter Styczynski | Reduction of hair growth |
| US7934284B2 (en) | 2003-02-11 | 2011-05-03 | Braun Gmbh | Toothbrushes |
| US7015349B2 (en) * | 2003-03-26 | 2006-03-21 | The Gillette Company | Reduction of hair growth |
| US7892563B2 (en) | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
| US20050031699A1 (en) * | 2003-06-26 | 2005-02-10 | L'oreal | Porous particles loaded with cosmetically or pharmaceutically active compounds |
| WO2005004984A1 (en) * | 2003-07-14 | 2005-01-20 | Power Paper Ltd. | Device and method for the treatment of pilosebaceous disorders |
| ES2702607T3 (es) | 2004-01-07 | 2019-03-04 | E L Man Corporation | Composición cosmética y método de retardo del crecimiento del vello |
| US20050249685A1 (en) * | 2004-04-27 | 2005-11-10 | Natalia Botchkareva | Reduction of hair growth |
| US20060034952A1 (en) * | 2004-08-13 | 2006-02-16 | Kondhalkar Mrinmayee B | Agent for inhibiting the growth of mammalian hair |
| CN101087568A (zh) * | 2004-12-22 | 2007-12-12 | 吉莱特公司 | 减少毛发生长 |
| CA2589762A1 (en) * | 2004-12-22 | 2006-06-29 | The Gillette Company | Reduction of hair growth with survivin inhibitors |
| US20060263438A1 (en) * | 2005-05-17 | 2006-11-23 | L'oreal | Gelled oil particles for targeting sebaceous glands and/or hair follicles |
| US7618956B2 (en) * | 2005-05-31 | 2009-11-17 | The Gillette Company | Reduction of hair growth |
| FR2890310B1 (fr) * | 2005-09-06 | 2009-04-03 | Sederma Soc Par Actions Simpli | Utilisation des protoberberines comme agents regulant l'activite de l'unite pilosebacee |
| US20070086972A1 (en) * | 2005-09-12 | 2007-04-19 | Jacob Birnbaum | Hair growth compositions and methods for treating hair loss or related conditions |
| GB0601684D0 (en) * | 2006-01-27 | 2006-03-08 | Reckitt Benckiser Uk Ltd | Composition, process for preparation and method of use |
| US7727516B2 (en) * | 2006-02-28 | 2010-06-01 | The Procter & Gamble Company | Reduction of hair growth |
| US20070246057A1 (en) * | 2006-04-20 | 2007-10-25 | Muller Sigfrid A | Ear treatment for excess hair |
| WO2009052518A2 (en) * | 2007-10-19 | 2009-04-23 | Aspen Benefits Group, Llc | Methods and compositions directed to reduction of facial hair hirsutism in females |
| PE20120116A1 (es) | 2008-11-05 | 2012-02-18 | Wyeth Llc | Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta hemolitica (bhs) |
| FR2944443B1 (fr) | 2009-04-21 | 2012-11-09 | Arkema France | Procede de fabrication de particules de poudre libre a base de polyamide impregnee, et particules de poudre libre a base de polyamide ayant une teneur d'au moins 25% en poids d'au moins un agent cosmetique ou pharmaceutique |
| FR2953716B1 (fr) | 2009-12-16 | 2015-03-27 | Oreal | Kit de formulation d'un produit cosmetique |
| JP5913136B2 (ja) * | 2010-02-08 | 2016-04-27 | プレーリー ファーマシューティカルズ、エルエルシー | 糖質コルチコイド感作物質としてのプロゲストーゲンの使用方法 |
| EP2735303A1 (en) | 2012-11-23 | 2014-05-28 | Pilosciences | Hair growth compositions and methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2350315C2 (de) * | 1973-10-06 | 1984-01-12 | Johnson & Johnson GmbH, 4000 Düsseldorf | Pharmazeutische und kosmetische Präparate zur äußerlichen Anwendung |
| US4201788A (en) * | 1976-10-20 | 1980-05-06 | University Patents, Inc. | Process for alleviating proliferative skin diseases |
| US4139563A (en) * | 1977-07-01 | 1979-02-13 | Merrell Toraude Et Compagnie | α-ACETYLENIC DERIVATIVES OF AMINES |
| IE47082B1 (en) * | 1977-07-01 | 1983-12-14 | Merrell Toraude & Co | -acetylenic amino acids |
| US4182891A (en) * | 1977-07-01 | 1980-01-08 | Merrell Toraude Et Compagnie | α-Acetylenic derivatives of α-amino acids |
| DE2840144A1 (de) * | 1978-09-15 | 1980-03-27 | Goedecke Ag | Topisch applizierbares arzneimittel mit antiandrogener wirkung |
| EP0016239B1 (de) * | 1979-03-27 | 1981-12-30 | Jürgen Prof. Dr. med. Tamm | Kosmetisches Haar- und Hautpflegemittel und dessen Herstellung |
| FR2492829A1 (fr) * | 1980-10-24 | 1982-04-30 | Oreal | Agents de surface non-ioniques derives du glucose, procede pour les preparer et compositions les contenant |
| DE3130644A1 (de) * | 1981-07-29 | 1983-02-17 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue androstan-derivate, verfahren zu ihrer herstellung und pharmazeutische praeparate, die diese verbindungen enthalten |
| US4439432A (en) * | 1982-03-22 | 1984-03-27 | Peat Raymond F | Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols |
-
1984
- 1984-10-15 US US06/661,019 patent/US4720489A/en not_active Expired - Lifetime
-
1985
- 1985-10-10 AT AT85905356T patent/ATE72978T1/de not_active IP Right Cessation
- 1985-10-10 AU AU48673/85A patent/AU590730B2/en not_active Expired
- 1985-10-10 WO PCT/US1985/002000 patent/WO1986002269A1/en not_active Ceased
- 1985-10-10 DE DE8585905356T patent/DE3585526D1/de not_active Expired - Lifetime
- 1985-10-10 EP EP85905356A patent/EP0198893B1/en not_active Expired - Lifetime
- 1985-10-10 CA CA000492728A patent/CA1262335A/en not_active Expired
- 1985-10-10 JP JP60504753A patent/JPH0653680B2/ja not_active Expired - Lifetime
- 1985-10-11 PH PH32920A patent/PH26283A/en unknown
- 1985-10-11 ZA ZA857846A patent/ZA857846B/xx unknown
- 1985-10-12 CN CN85108498A patent/CN1045160C/zh not_active Expired - Lifetime
- 1985-10-14 MX MX026863A patent/MX172116B/es unknown
- 1985-10-14 NZ NZ213805A patent/NZ213805A/xx unknown
- 1985-10-15 EG EG655/85A patent/EG17746A/xx active
- 1985-10-15 GR GR852488A patent/GR852488B/el unknown
-
1986
- 1986-06-11 NO NO862339A patent/NO174832C/no not_active IP Right Cessation
- 1986-06-13 DK DK278486A patent/DK166801B1/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EG17746A (en) | 1990-10-30 |
| DK278486A (da) | 1986-06-13 |
| DK278486D0 (da) | 1986-06-13 |
| GR852488B (zh) | 1986-02-03 |
| NZ213805A (en) | 1993-04-28 |
| JPS62500932A (ja) | 1987-04-16 |
| CN85108498A (zh) | 1986-06-10 |
| WO1986002269A1 (en) | 1986-04-24 |
| AU590730B2 (en) | 1989-11-16 |
| ATE72978T1 (de) | 1992-03-15 |
| PH26283A (en) | 1992-04-10 |
| DE3585526D1 (de) | 1992-04-09 |
| US4720489A (en) | 1988-01-19 |
| NO862339L (no) | 1986-06-11 |
| EP0198893A1 (en) | 1986-10-29 |
| JPH0653680B2 (ja) | 1994-07-20 |
| ZA857846B (en) | 1986-05-28 |
| NO174832B (no) | 1994-04-11 |
| NO174832C (no) | 1994-07-20 |
| EP0198893B1 (en) | 1992-03-04 |
| CA1262335A (en) | 1989-10-17 |
| NO862339D0 (no) | 1986-06-11 |
| MX172116B (es) | 1993-12-03 |
| EP0198893A4 (en) | 1988-05-10 |
| DK166801B1 (da) | 1993-07-19 |
| AU4867385A (en) | 1986-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1045160C (zh) | 毛发生长修饰剂 | |
| RU2567792C2 (ru) | Композиции и способы стимулирования роста волос | |
| CN102159179B (zh) | 防止、治疗脱发或促进毛发生成的成分 | |
| JP4801150B2 (ja) | 発毛の低減 | |
| CN103596550A (zh) | 用于预防脱发和促进毛发生长的局部施用的组合物 | |
| CN116036018B (zh) | 一种泡沫型生发液及其制备方法 | |
| AU2010332759B2 (en) | Use of 2,3-dihydroxypropyl dodecanoate for treating seborrhoea | |
| CN1082398A (zh) | 含有松树提取物的可外用生发剂 | |
| DK2060261T3 (en) | C-19 steroids for cosmetic use | |
| CN1070702C (zh) | 2,4-二氨基嘧啶-3-氧化物或其盐在治疗胶原成熟和组织化失调中的应用 | |
| CN85101410A (zh) | 毛发生长的改变 | |
| HUE027440T2 (en) | C-19 steroids for specific medical applications | |
| Foy et al. | Estrogen and hippocampal synaptic plasticity | |
| JP2007501832A6 (ja) | テルビナフィンおよびヒドロコルチゾンを含んでいる局所組成物 | |
| JP2007501832A (ja) | テルビナフィンおよびヒドロコルチゾンを含んでいる局所組成物 | |
| US8580236B2 (en) | Hair sustaining formulation | |
| CN1070369C (zh) | 毛发生长的改变 | |
| CN1946372A (zh) | 使用热休克蛋白抑制剂来减少毛发生长 | |
| RU2732295C1 (ru) | Препарат для укрепления и стимулирования роста волос и способ его использования | |
| JP7389748B2 (ja) | フィトステノンの新規用途 | |
| NO312573B1 (no) | Anvendelse av et vitamin A-derivat og et kortikosteroid til behandling av hårtap | |
| FR2477871A1 (fr) | Composition destinee a etre utilisee sur le cuir chevelu, notamment pour le traitement des calvities naissantes | |
| JPH02275815A (ja) | 5α−リダクターゼ活性阻害剤 | |
| Aboul Serour | Polycystic Ovarian Syndrome and Hirsutism | |
| Watson et al. | Testosterone hormone replacement and its alternatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C53 | Correction of patent of invention or patent application | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: PATENTEE; FROM: JOHN JOSEPH H DEILMANN TO: THE GILLETTE COMPANY |
|
| CP03 | Change of name, title or address |
Address after: Massachusetts, USA Patentee after: Gillette Co. Address before: American New York Patentee before: Douglas Shander |
|
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |